CordenPharma entered the synthetic Oligonucleotide manufacturing arena in CordenPharma Colorado. With a two phase investment, the strategic expansion will provide pharma and biopharma customers with a fully-integrated API to drug product service offering organized under a new Oligonucleotides Platform. Phase one is the reconditioning of existing lab space, purchase of development equipment, and hiring of an expert team to set up process and analytical development capabilities, with a target c...